^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPI-361175

    i
    Other names: BPI-361175
    Company:
    Betta Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    2ms
    BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Xcovery Holdings, Inc. | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    EGFR mutation
    |
    BPI-361175
    8ms
    A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. (PubMed, Bioorg Med Chem)
    This review delves into the current clinical status, efficacy, safety profiles, and regulatory approvals of third-generation EGFR TKIs, including Osimertinib, Lazertinib, Furmonertinib, Aumolertinib, Rezivertinib, Befotertinib, Sunvozertinib...Notable fourth-generation candidates such as TQB3804, BPI-361175, BDTX-1535, WJ13404, QLH11811, H002, HS-10375, BBT-207, JIN-A02, and HS-10504 are highlighted for their potential to overcome the C797S mutation...By evaluating the therapeutic potential and limitations of these EGFR TKIs, this review aims to guide future research in the management of EGFR-mutant NSCLC. This acts as guiding beacon for the strategic design and development of third and fourth generation EGFR-TK inhibitors to overcome the drug resistance hurdles in the development of EGFR-TK inhibitors.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    Tagrisso (osimertinib) • Ameile (aumolertinib) • Ivesa (firmonertinib) • Lazcluze (lazertinib) • JIN-A02 • silevertinib (BDTX-1535) • Semena (befotertinib) • Zegfrovy (sunvozertinib) • Rui Bi Da (rezivertinib) • BPI-361175 • BBT-207 • HS-10375 • QLH11811 • TQB3804
    over3years
    A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    BPI-361175